Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase Inhibition.
Angeli, A., Ferraroni, M., Capperucci, A., Tanini, D., Costantino, G., Supuran, C.T.(2022) ChemMedChem 17: e202200085-e202200085
- PubMed: 35238480 
- DOI: https://doi.org/10.1002/cmdc.202200085
- Primary Citation of Related Structures:  
7QBH - PubMed Abstract: 
A study on the activity of selenocarbamates as a novel chemotype acting as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors is reported. Undergoing CA-mediated hydrolysis, selenocarbamates release selenolates behaving as zinc binding groups and effectively inhibiting CAs. A series of selenocarbamates characterised by high molecular diversity and complexity have been studied against different human CA isoforms such as hCA I, II, IX and XII. Selenocarbamates behave as masked selenols with potential biological applications as prodrugs for CAs inhibition-based strategies. X-ray studies provided insights into the binding mode of this novel class of CA inhibitors.
Organizational Affiliation: 
Department NEUROFARBA, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy.